INVESTOR ALERT: Investigation of Tokai Pharmaceuticals Announced by Holzer & Holzer LLC
26 Juli 2016 - 5:46PM
Business Wire
Holzer & Holzer, LLC is investigating whether statements
made by Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”)
(NASDAQ: TKAI) regarding its business and operations complied with
federal securities laws. On July 26, 2016, Tokai announced that it
was ending a late-stage trial of galeterone, its potential prostate
cancer therapy. The Company stated that it did not believe the
phase 3 study would meet its primary endpoint. The price of Tokai
stock fell dramatically following the announcement.
If you purchased Tokai common stock and suffered a loss on that
investment, you are encouraged to contact Corey D. Holzer, Esq. at
cholzer@holzerlaw.com or via toll-free telephone at (888) 508-6832,
to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that
dedicates its practice to vigorous representation of shareholders
and investors in litigation nationwide, including shareholder class
action and derivative litigation. More information about the firm
is available through its website, www.holzerlaw.com and upon
request from the firm. Holzer & Holzer, LLC has paid for the
dissemination of this promotional communication, and Corey D.
Holzer is the attorney responsible for its content.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160726006150/en/
Holzer & Holzer, LLCCorey D. Holzer, Esq., 888-508-6832
(toll-free)cholzer@holzerlaw.com
Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
Echtzeit-Nachrichten über Novus Therapeutics Inc (NASDAQ): 0 Nachrichtenartikel
Weitere Tokai Pharmaceuticals, Inc. (MM) News-Artikel